FI952170L - Koagulaatiota edistävää aktiivista ainetta sisältävä stabiili valmisteveren koagulaatiosairauksien hoitamiseksi - Google Patents

Koagulaatiota edistävää aktiivista ainetta sisältävä stabiili valmisteveren koagulaatiosairauksien hoitamiseksi Download PDF

Info

Publication number
FI952170L
FI952170L FI952170A FI952170A FI952170L FI 952170 L FI952170 L FI 952170L FI 952170 A FI952170 A FI 952170A FI 952170 A FI952170 A FI 952170A FI 952170 L FI952170 L FI 952170L
Authority
FI
Finland
Prior art keywords
treatment
active substance
product containing
coagulation
stable product
Prior art date
Application number
FI952170A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI952170A7 (fi
FI952170A0 (fi
Inventor
Johann Eibl
Hans Peter Schwarz
Juergen Siekmann
Peter Turecek
Original Assignee
Immuno Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno Ag filed Critical Immuno Ag
Publication of FI952170A0 publication Critical patent/FI952170A0/fi
Publication of FI952170A7 publication Critical patent/FI952170A7/fi
Publication of FI952170L publication Critical patent/FI952170L/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
FI952170A 1994-05-06 1995-05-05 Koagulaatiota edistävää aktiivista ainetta sisältävä stabiili valmisteveren koagulaatiosairauksien hoitamiseksi FI952170L (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4416180A DE4416180C2 (de) 1994-05-06 1994-05-06 Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen und Verfahren zur Herstellung dieses Präparats

Publications (3)

Publication Number Publication Date
FI952170A0 FI952170A0 (fi) 1995-05-05
FI952170A7 FI952170A7 (fi) 1995-11-07
FI952170L true FI952170L (fi) 1995-11-07

Family

ID=6517576

Family Applications (1)

Application Number Title Priority Date Filing Date
FI952170A FI952170L (fi) 1994-05-06 1995-05-05 Koagulaatiota edistävää aktiivista ainetta sisältävä stabiili valmisteveren koagulaatiosairauksien hoitamiseksi

Country Status (7)

Country Link
EP (1) EP0680763A3 (fr)
JP (1) JPH0840928A (fr)
AT (1) ATA77095A (fr)
CA (1) CA2148672A1 (fr)
DE (1) DE4416180C2 (fr)
FI (1) FI952170L (fr)
NO (1) NO951762L (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4416166C2 (de) * 1994-05-06 1997-11-20 Immuno Ag Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen
DK0796623T3 (da) * 1996-03-20 2005-08-01 Baxter Ag Farmaceutisk præparat til behandling af blodkoagulationslidelser
AU4709399A (en) * 1998-06-23 2000-01-10 Victor J. Marder Phospholipid vesicle-tissue factor complex preparations and methods of making and using same
US7056529B2 (en) * 2002-05-14 2006-06-06 University Of Louisville Research Foundation, Inc. Direct cellular energy delivery system
WO2007117469A2 (fr) 2006-03-30 2007-10-18 The Research Foundation Of State University Of New York Compositions de complexes protéine-lipide moins immunogéniques et à circulation prolongée
WO2016123804A1 (fr) 2015-02-06 2016-08-11 Guangzhou Bioseal Biotech Co., Ltd. Procédé de préparation de thrombine
CN116019960A (zh) * 2018-10-17 2023-04-28 东丽株式会社 止血材料
JP6772322B2 (ja) * 2019-03-01 2020-10-21 コウシュウ・バイオシール・バイオテック・カンパニー・リミテッドＧｕａｎｇｚｈｏｕ Ｂｉｏｓｅａｌ Ｂｉｏｔｅｃｈ Ｃｏ．， Ｌｔｄ． トロンビンの調製のための方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348384A (en) * 1980-10-17 1982-09-07 Dainippon Pharmaceutical Co., Ltd. Pharmaceutical composition for oral administration containing coagulation factor VIII or IX
JPS5770814A (en) * 1980-10-17 1982-05-01 Isamu Horikoshi Oral preparation of blood clotting eighth factor
GB2129685B (en) * 1982-11-11 1985-11-13 Nat Biolog Standards Board Anti-haemophilic compositions
US4610880A (en) * 1983-06-27 1986-09-09 Queen's University At Kingston Composition for controlling hemophilia in mammals
US4721618A (en) * 1983-06-27 1988-01-26 Queen's University At Kingston Method for controlling bleeding
AT389815B (de) * 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
WO1990003808A1 (fr) * 1988-10-07 1990-04-19 The Liposome Company, Inc. Traitement thermique de liposomes
WO1991002532A2 (fr) * 1989-08-14 1991-03-07 Queen's University At Kingston Procede de stimulation de l'effet fibrinolytique
US5504064A (en) * 1991-04-10 1996-04-02 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with an activator of FVII
EP0815852A1 (fr) * 1993-08-06 1998-01-07 Opperbas Holding B.V. Procédé de haut chargement de vehicules avec des biopolymères
DE4416166C2 (de) * 1994-05-06 1997-11-20 Immuno Ag Stabiles Präparat zur Behandlung von Blutgerinnungsstörungen

Also Published As

Publication number Publication date
DE4416180C2 (de) 1997-08-14
CA2148672A1 (fr) 1995-11-07
FI952170A7 (fi) 1995-11-07
FI952170A0 (fi) 1995-05-05
EP0680763A3 (fr) 1998-01-28
DE4416180A1 (de) 1995-11-09
NO951762L (no) 1995-11-07
EP0680763A2 (fr) 1995-11-08
ATA77095A (de) 2002-04-15
NO951762D0 (no) 1995-05-05
JPH0840928A (ja) 1996-02-13

Similar Documents

Publication Publication Date Title
FI952169A0 (fi) Stabiili valmiste veren koagulaatiohäiriöiden hoitamiseksi
DE69929996D1 (de) Pharmazeutisches mittel zur behandlung von diabetes
ATE252901T1 (de) Arzneimittel zur behandlung von entzündlichen herzkrankheiten
DE69412552D1 (de) Medizinisches Instrument zur Behandlung von Sinusitis
HUP9700603A3 (en) Pharmaceutical preparation for the treatment of blood coagulation disorders
DE69307509D1 (de) Vorrichtung zur behandlung von herzfehlern
DE69124293D1 (de) Vorrichtung zur Behandlung von Wirbelsäulenerkrankungen
DE69927823T2 (de) Hydrogel für die therapeutische behandlung von aneurysmas
ATE235481T1 (de) Substituierte benzopyranderivate zur behandlung von entzündungen
DE60023128D1 (de) Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen
DE69626539D1 (de) topische Verwendung von Vitamin D zur Behandlung von Augenerkrankungen
ATE201992T1 (de) Carbostyrilderivat zur behandlung von ophthalmologischen erkrankungen
DE69824576D1 (de) Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen
DE69620691D1 (de) Therapeutisches Mittel zur Behandlung der Hypercholesterinämie
BG94738A (bg) Използване на разтвор на йод за лечение на заболявания, свързани с йодна недостатъчност
IT1290781B1 (it) Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
DE69829217D1 (de) Vorrichtung zur therapeutischen behandlung von blutgefässen
FI952170A7 (fi) Koagulaatiota edistävää aktiivista ainetta sisältävä stabiili valmisteveren koagulaatiosairauksien hoitamiseksi
NO20012106D0 (no) Middel for behandling av benpatobolisme
DE69735417D1 (de) 2,5-dihydroxybenzylsulfonderivate zur behandlung von sexuellen störungen
ATA113492A (de) Mehrfachbeutelsystem zur sterilen behandlung von menschlichen blutkonserven
DE69739190D1 (de) Arzneimittel zur behandlung von oculären kreislauferkrankungen
DE68901172D1 (de) (-)-2-pyrazolinverbindung, deren optischen aufspaltung und therapeutisches agens zur behandlung von zerebralen gefaesskrankheiten, diese verbindung als aktives ingredient enthaltend.
DE69522685D1 (de) Behandlung von blut-plasma
DE68905076D1 (de) Pharmazeutische zusammensetzung fuer die behandlung von hautwunden.